Intermittent fasting – periods of eating little or nothing interspersed with normal food consumption – isn't an effective way ...
Following the frequent suspicions regarding the safety of cholesterol-lowering drugs in the pre-statin era,1 statins have been a recurrent object of various concerns and alarming news. For example, ...
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial Earlier detection of cancer offers an opportunity to ...
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta–selective agonist in development for ...
Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...
Elemento is the director of the Englander Institute for Precision Medicine at Weill Cornell Medicine. Sternberg is the clinical director of the Englander Institute for Precision Medicine. Khozin is ...
Research indicates that many statin therapy side effects are not supported by evidence, suggesting a need for revised ...
Statin labels should be revised to reflect their safety and to hopefully spur better uptake and adherence, say experts.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results